Rafic Farah
Medical Oncology · Seattle, WANPI 1780760587
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,481 of the $114,471 with a category attached, or 69.4%. 11 manufacturers reported payments, led by ADC Therapeutics America, Inc. at 58.4% of the total. 2025 is the largest year on record at $99,753, 6.9 times the $14,508 reported in 2019. Among medical oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $1122.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$67K
- Incyte Corporation$20K
- Gilead$11K
- Bristol Myers Squibb$7K
- AbbVie$6K
- Bayer$2K
- plus $2K from 5 others
Across 22 payments — averaging $4323.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$29K
- Verastem, Inc.$26K
- Karyopharm Therapeutics Inc.$24K
- Secura Bio, Inc.$15K
- National Marrow Donor Program$1K
What the payments were for
- Consulting fees$16,46314%
- Speaking & faculty fees$79,48169%
- Travel & lodging$15,45013%
- Food & beverage$2,9893%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 46 | $66,799 |
| Incyte Corporation | 15 | $19,578 |
| Gilead | 12 | $10,814 |
| Bristol Myers Squibb | 5 | $7,314 |
| AbbVie | 16 | $6,289 |
| Bayer | 1 | $1,700 |
| Sanofi US Services Inc. | 2 | $1,546 |
| AstraZeneca | 2 | $206 |
| Johnson & Johnson | 1 | $106 |
| Secura Bio, Inc. | 1 | $98 |
| Merck | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,471 in reported general payments places this provider in the 90th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 47 | $716,460 |
| Lenalidomide | 45 | $666,251 |
| VenclextaVenetoclax | 76 | $582,965 |
| XospataGilteritinib Fumarate | 26 | $535,215 |
| JaypircaPirtobrutinib | 21 | $458,748 |
| RevlimidLenalidomide | 27 | $442,504 |
| PomalystPomalidomide | 12 | $271,687 |
| ImbruvicaIbrutinib | 18 | $255,639 |
| BrukinsaZanubrutinib | 12 | $155,942 |
| InqoviDecitabine/Cedazuridine | 16 | $132,487 |
| Posaconazole | 27 | $35,057 |
| EliquisApixaban | 39 | $20,575 |
| Acyclovir | 482 | $5,915 |
| Enoxaparin Sodium | 12 | $3,514 |
| Magnesium Sulfate | 11 | $1,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $206 | $716,46047 claims |
| AbbVieVenclexta | $6,289 | $582,96576 claims |
| Bristol Myers SquibbRevlimid | $7,314 | $442,50427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
- Diane TsengSeattle$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.